InsidersTradesSigma
Track the SPYRE THERAPEUTICS INC stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €8bn. The latest transaction was disclosed on 7 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: SESSIONS, LLC. The full history is free.
Analysts rate SPYRE THERAPEUTICS INC Strong Buy (bullish), based on 14 analysts. Average price target: US$119.71.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
SPYRE THERAPEUTICS INC es una empresa enfocada en el desarrollo de terapias innovadoras para enfermedades graves. Cotiza en el mercado XNAS.